Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. After experiencing losses in the second quarter, small-cap stocks notably increased in the third quarter. The Russell 2000 Growth Index (up 8.41%) underperformed the Russell 2000 Value Index (up 10.11%). In addition, please check the fund’s top five holdings to know its best picks in 2024.

Carillon Eagle Small Cap Growth Fund highlighted stocks like Lantheus Holdings, Inc. (NASDAQ:LNTH), in the third quarter 2024 investor letter. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company that manufactures diagnostic and therapeutic products used by healthcare providers to diagnose and treat heart, cancer, and other medical conditions. The one-month return of Lantheus Holdings, Inc. (NASDAQ:LNTH) was -18.68%, and its shares gained 29.77% of their value over the last 52 weeks. On November 26, 2024, Lantheus Holdings, Inc. (NASDAQ:LNTH) stock closed at $89.53 per share with a market capitalization of $6.225 billion.

Carillon Eagle Small Cap Growth Fund stated the following regarding Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q3 2024 investor letter:

"Lantheus Holdings, Inc. (NASDAQ:LNTH) is a fully integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence (AI) solutions used to fight serious medical conditions. The company had a strong quarter that exceeded revenue expectations, highlighted by the Centers for Medicare and Medicaid Services’ (CMS) proposed update to reimbursement policies, ensuring separate outpatient reimbursement for Lantheus’s flagship product, PYLARIFY, a prostate cancer diagnostic imaging agent. This came just in time as the company’s traditional pass-through payment status was about to expire, alleviating potential revenue pressure. Additionally, Lantheus has a promising pipeline of diagnostic radiopharmaceuticals to support future growth."

A medical professional performing a pulmonary function assessment on a patient.

Lantheus Holdings, Inc. (NASDAQ:LNTH) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Lantheus Holdings, Inc. (NASDAQ:LNTH) at the end of the third quarter which was 34 in the previous quarter. Lantheus Holdings, Inc.'s (NASDAQ: LNTH) consolidated net revenue for the third quarter was approximately $378.7 million, representing an 18.4% increase year-over-year. While we acknowledge the potential of Lantheus Holdings, Inc. (NASDAQ:LNTH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.